Ribavirin
- Generic Name
- Ribavirin
- Brand Names
- Ibavyr, Rebetol, Virazole
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 36791-04-5
- Unique Ingredient Identifier
- 49717AWG6K
- Background
Producing a broad-spectrum activity against several RNA and DNA viruses, Ribavirin is a synthetic guanosine nucleoside and antiviral agent that interferes with the synthesis of viral mRNA. It is primarily indicated for use in treating hepatitis C and viral hemorrhagic fevers. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes...
- Indication
Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (SVR). Typically added to improve SVR and reduce relapse rates .
...
- Associated Conditions
- Chronic Hepatitis C Virus (HCV) Infection, Severe Respiratory Syncytial Virus Infection
- Associated Therapies
- -
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
- Conditions
- Interventions
- First Posted Date
- 2006-05-10
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 372
- Registration Number
- NCT00323804
- Locations
- 🇫🇷
Service d'Hépatogastroentérologie - CH La Roche sur Yon, La Roche sur Yon, France
🇫🇷Service d'Hépatogastroentérologie - CH Montélimar, Montelimar, France
🇫🇷Centre Hospitalier, Saint Quentin, France
Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine
- Conditions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2010-10-28
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 30
- Registration Number
- NCT00310336
- Locations
- 🇨🇭
University Hospital Basel, Basel, BS, Switzerland
A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)
- Conditions
- Interventions
- First Posted Date
- 2006-03-20
- Last Posted Date
- 2010-06-03
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 180
- Registration Number
- NCT00304551
- Locations
- 🇯🇵
Tohoku Region, Tohoku, Japan
🇯🇵Hokkaido Region, Hokkaido, Japan
🇯🇵Kyusyu Region, Kyusyu, Japan
Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4
- First Posted Date
- 2006-01-18
- Last Posted Date
- 2008-02-26
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 280
- Registration Number
- NCT00277862
- Locations
- 🇪🇬
MISR Welding, Cairo, Egypt
🇪🇬ELectricity Auth, Mynia and Cairo, Egypt
🇪🇬AUS Specialized Hospital,, Cairo;, Cairo,, Egypt
Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I
- Conditions
- Interventions
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2008-03-07
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 18
- Registration Number
- NCT00277758
- Locations
- 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C
- Conditions
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 12
- Registration Number
- NCT00262483
- Locations
- 🇵🇷
Call for information, Santurce, Puerto Rico
Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)
- Conditions
- Interventions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 121
- Registration Number
- NCT00255008
Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)
- Conditions
- Interventions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 146
- Registration Number
- NCT00255034
Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2005-11-03
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 150
- Registration Number
- NCT00248339
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Timing and Duration of Acute Hepatitis C Treatment
- Conditions
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2006-09-11
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 180
- Registration Number
- NCT00241618
- Locations
- 🇪🇬
Shebin Liver Center, Cairo, Egypt
🇪🇬ASU Specialized Hospital, Cairo, Egypt
🇪🇬ASU, Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.